Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
April 01, 2019 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
March 28, 2019 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
March 21, 2019 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
March 18, 2019 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
February 21, 2019 16:05 ET
|
Opiant Pharmaceuticals, Inc.
-Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus remains on advancing lead product candidate, OPNT003, for treatment of...
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
December 26, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today...
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
December 24, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 24, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 07, 2018 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
November 05, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing...
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
November 01, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...